Kissei Pharmaceutical Co., Ltd

Industry

  • Pharmaceuticals
    • Nutraceuticals
    • Generic Drugs
    • Vaccines
    • Specialty Pharmaceuticals
  • Biotechnology
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products

Other Names/Subsidiaries

  • Kissei Yakuhin Kogyo
  • Kissei America
  • Tachibana Seikagaku Institute
See more in Biomedtracker

Latest on Kissei Pharmaceutical Co., Ltd

Scrip

Asia Deal Watch: EpimAb Licenses Bispecific Antibody To Newly Formed Vignette

 
• By Joseph Haas, Dexter Jie Yan, Xu Hu, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Vignette Gets Rights To BCMA×CD3 Bispec

Scrip

Japan Phase III Wins, Asian Alliances Buoy Kissei's Linzagolix

 
• By Lisa Takagi

A previous regulatory setback in the US for Kissei Pharmaceutical Co., Ltd ’s female health product linzagolix has not discouraged the Japanese firm from continued development of the oral gonadotropi

Scrip

Asia Deal Watch: Chugai Extends Relationship With Helsinn

 
• By Joseph Haas, Vibha Ravi, Dexter Jie Yan, Lisa Takagi, and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Helsinn Extends Akynzeo Marketing

In Vivo

Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else

 
• By Bridget Silverman

A beneficial effect of sponsorship by the largest companies in the pharma industry can be seen in the fates of novel agent applications that faced US FDA approval decisions in recent years: the applic